49 results on '"Stilgenbauer, Stephan"'
Search Results
2. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib
3. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor‐risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial
4. TP53 mutation and survival in aggressive B cell lymphoma
5. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial
6. Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase
7. Telomere dysfunction and chromothripsis
8. Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia
9. Mutations driving CLL and their evolution in progression and relapse
10. Supplement to: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
11. Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia
12. Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkinʼs Lymphomas: A Glycoengineered Type II CD20 Antibody
13. Loss of cooperativity of secreted CD40L and increased dose–response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6
14. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation
15. Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach
16. Resistance Mechanisms for the Brutonʼs Tyrosine Kinase Inhibitor Ibrutinib
17. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
18. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
19. The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients
20. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
21. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia
22. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
23. The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p
24. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia
25. Nurse-like cells show deregulated expression of genes involved in immunocompetence
26. Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL
27. Chronic Lymphocytic Leukemia: New Concepts for Future Therapy
28. SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL)
29. High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay
30. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells
31. Danish CLL2-Study revisited: FISH on a cohort with a 20-yr follow-up confirms the validity of the hierarchical model of genomic aberrations in chronic lymphocytic leukaemia
32. Fatal Ophiostoma piceae infection in a patient with acute lymphoblastic leukaemia
33. Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis
34. Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia
35. High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia
36. Update on Genomic Profiling in Chronic Lymphocytic Leukemia
37. Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse
38. Cytogenetic Abnormalities Can Change During the Course of the Disease Process in Chronic Lymphocytic Leukemia
39. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer
40. Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia
41. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II study
42. Evidence for Distinct Pathomechanisms in Genetic Subgroups of Chronic Lymphocytic Leukemia Revealed by Quantitative Expression Analysis of Cell Cycle, Activation, and Apoptosis-Associated Genes
43. Microarray Gene Expression Profiling of B-Cell Chronic Lymphocytic Leukemia Subgroups Defined by Genomic Aberrations and VH Mutation Status
44. Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma
45. Capillary electrophoretic analysis of genomic DNA methylation levels
46. Campath-1H-Induced Complete Remission of Chronic Lymphocytic Leukemia despite p53 Gene Mutation and Resistance to Chemotherapy
47. Chromosomal Abnormalities in Chronic Lymphocytic Leukemia
48. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
49. CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.